NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球CAR-T細胞療法市場:到2028年的行業趨勢和預測

Global CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028

出版商 Data Bridge Market Research Private Limited 商品編碼 1003672
出版日期 內容資訊 英文 432 Pages
商品交期: 3-5個工作天內
價格
全球CAR-T細胞療法市場:到2028年的行業趨勢和預測 Global CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028
出版日期: 2021年03月01日內容資訊: 英文 432 Pages
簡介

在預測期2021-2028年,全球CAR-T細胞療法市場預計將以30%的複合年增長率增長。促進市場增長的關鍵因素包括在癌症和傳染病治療中增加使用CAR-T細胞療法,以及提高對免疫療法的認識。

本報告調查了全球CAR-T細胞療法市場,包括市場增長和限制因素,機遇與挑戰,產品/結構/目標抗原/品牌/品牌/治療應用/最終用戶/分銷渠道/其提供了諸如區域性等信息市場分析,競爭條件和主要公司的概況。

目錄

第1章簡介

第2章市場細分

第3章執行摘要

第4章重要注意事項

第5章流行病學

第6章管道分析

第7章市場概述

  • 成長要因
    • 越來越多地使用CAR-T細胞療法來治療癌症和傳染病
    • 癌症患病率上升
    • 提高對免疫療法的認識
    • 增加研發投入
    • 新興市場採用CAR-T細胞療法
  • 抑制要因
    • 治療的副作用
    • 與治療相關的高昂費用
    • 與CAR-T治療相關的後勤挑戰
    • 可供選擇的腫瘤治療方法
  • 市場機會
    • 管道產品的存在
    • 市場進入公司的戰略舉措
    • 醫療保健支出的增加
  • 挑戰
    • 免疫療法的批准期長
    • 缺乏熟練的專業人員

第8章COVID-19對全球CAR-T細胞療法市場的影響

  • 對價格的影響
  • 對需求的影響
  • 對供應鏈的影響
  • 製造商的戰略決策
  • 結論

第9章全球CAR-T細胞治療市場:副產品

  • 概述
  • 自體CAR-T細胞
  • 同種CAR-T細胞

第10章全球CAR-T細胞治療市場:按結構劃分

  • 概述
  • 第一代CAR-T細胞
  • 第二代CAR-T細胞
  • 第三代CAR-T細胞
  • 第四代CAR-T細胞

第11章全球CAR-T細胞治療市場:按靶抗原分類

  • 概述
  • 血液惡性腫瘤抗原
    • CD-19
    • CD-30
    • CD-22
    • CD-20
    • CD-33
  • 實體瘤抗原
    • 人表皮生長因子受體2(HER-2)
    • 表皮生長因子受體變體III□□(EGFRV-III)
    • 中腦甘油(MSLN)
    • 前列腺特異性膜抗原(PSMA)
    • 白介素13RA2(IL13RA2)
    • 二硫代神經節甘脂2(GD2)
    • Glypican-3(GPC3)
    • 其他
  • 其他

第12章全球CAR-T細胞治療市場:按品牌劃分

  • 概述
  • YESCARTA
  • KYMRIAH
  • TECARTUS
  • 其他

第13章全球CAR-T細胞療法市場:按治療應用

  • 概述
  • 濾泡性淋巴瘤
  • 瀰漫性大B細胞淋巴瘤
  • 急性淋巴細胞白血病(全部)
  • 套細胞淋巴瘤
  • 多發性骨髓瘤
  • 血液系統惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 骨髓瘤
    • 其他
  • 肺癌
  • 慢性淋巴細胞性白血病
  • 胃癌
  • 胰腺癌
  • 乳腺癌
  • 其他

第14章全球CAR-T細胞治療市場:最終用戶

  • 概述
  • 醫院
  • 專科診所
  • 其他

第15章全球CAR-T細胞治療市場:通過分銷渠道

  • 概述
  • 醫院藥房
  • 其他

第16章全球CAR-T細胞治療市場:按地區

  • 概述
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 瑞士
    • 比利時
    • 土耳其
    • 奧地利
    • 挪威
    • 匈牙利
    • 立陶宛
    • 愛爾蘭
    • 波蘭
    • 其他
  • 亞太地區
    • 日本
    • 澳大利亞
    • 新加坡
    • 中國
    • 韓國
    • 印度
    • 馬來西亞
    • 泰國
    • 印度尼西亞
    • 菲律賓
    • 越南
    • 其他
  • 南美洲
    • 巴西
    • 阿根廷
    • 秘魯
    • 其他
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 南非
    • 以色列
    • 科威特
    • 埃及
    • 其他

第17章全球CAR-T細胞療法市場:公司狀況

  • 企業份額分析:全球
  • 企業份額分析:北美
  • 企業份額分析:歐洲
  • 企業份額分析:亞太地區

第18章SWOT分析

第19章公司簡介

  • KITE PHARMA (A SUBSIDIARY OF GILEAD SCIENCES, INC.)
  • NOVARTIS AG
  • ABBVIE INC.
  • ADAPTIMMUNE THERAPEUTICS PLC
  • AMGEN INC.
  • ATARA BIOTHERAPEUTICS, INC.
  • AURORA BIOPHARMA
  • AUTOLUS
  • BELLICUM PHAMACEUTICALS, INC.
  • BIOATLA INC.
  • BLUEBIRD BIO, INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • CARINA BIOTECH
  • CARTHERICS PTY LTD
  • CARTESIAN THERAPEUTICS, INC.
  • CELLECTIS SA
  • CELYAD ONCOLOGY SA
  • JOHNSON & JOHNSON SERVICES, INC.
  • SORRENTO THERAPEUTICS, INC.
  • TC BIOPHARM LIMITED
  • TESSA THERAPEUTICS LTD.
  • TMUNITY THERAPEUTICS
  • MUSTANG BIO
  • XYPHOS (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
  • ZIOPHARM ONCOLOGY, INC.

第20章調查表

第21章相關報告

目錄

Global CAR-T cell therapy treatment market is projected to register a CAGR of 30.0% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Global CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells, Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, Fourth Generation CAR-T Cells), Targeted Antigens (Antigens on Solid Tumors, Antigens on Hematologic Malignancies, Others), Brand (Yescarta, Kymriah, Tecartus, Others), Therapeutic Application (Hematological Malignancies, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Others), End User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospitals Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of global CAR-T cell therapy treatment market are:

Increase in usage of CAR-T cell therapy for the treatment of cancer and infectious diseases

Rise in awareness about immunotherapies

Market Players:

The key market players for global CAR-T cell therapy treatment market are listed below:

Autolus

Atara Biotherapeutics, Inc.

Amgen Inc.

Bellicum Phamaceuticals, Inc.

bluebird bio, inc.,

Adaptimmune Therapeutics plc

Bristol-Myers Squibb Company

Xyphos (a subsidiary of Astellas Pharma Inc.)

Johnson & Johnson Services, Inc.

BioAtla Inc.

AbbVie Inc.

Novartis AG

Kite Pharma (a subsidiary of Gilead Sciences, Inc.)

Aurora Biopharma

Tmunity Therapeutics

Cartherics Pty ltd

CARINA BIOTECH

Ziopharm Oncology, Inc.

Cellectis SA

Mustang Bio

Sorrento Therapeutics, Inc.

Cartesian Therapeutics, Inc.

TC BioPharm Limited

Celyad Oncology SA

Tessa Therapeutics Ltd.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL CAR-T CELL THERAPY TREATMENT MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 PRODUCT LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 MARKET PRODUCT COVERAGE GRID
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS

7 MARKET OVERVIEW

  • 7.1 DRIVERS
    • 7.1.1 INCREASE IN USAGE OF CAR-T CELL THERAPY FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
    • 7.1.2 INCREASING PREVALENCE OF CANCER
    • 7.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES
    • 7.1.4 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT
    • 7.1.5 ADOPTION OF CAR-T CELL THERAPY TREATMENT IN EMERGING MARKETS
  • 7.2 RESTRAINTS
    • 7.2.1 ADVERSE SIDE EFFECTS OF THERAPIES
    • 7.2.2 HIGH COST ASSOCIATED WITH THERAPIES
    • 7.2.3 LOGISTIC CHALLENGE ASSOCIATED WITH CAR-T THERAPIES
    • 7.2.4 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT
  • 7.3 OPPORTUNITIES
    • 7.3.1 PRESENCE OF PIPELINE PRODUCTS
    • 7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
    • 7.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
  • 7.4 CHALLENGES
    • 7.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES
    • 7.4.2 LACK OF SKILLED PROFESSIONALS

8 IMPACT OF COVID-19 ON GLOBAL CAR-T CELL THERAPY TREATMENT MARKET

  • 8.1 IMPACT ON PRICE
  • 8.2 IMPACT ON DEMAND
  • 8.3 IMPACT ON SUPPLY CHAIN
  • 8.4 STRATEGIC DECISION FOR MANUFACTURERS
  • 8.5 CONCLUSION

9 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT

  • 9.1 OVERVIEW
  • 9.2 AUTOLOGOUS CAR-T CELLS
  • 9.3 ALLOGENEIC CAR-T CELLS

10 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE

  • 10.1 OVERVIEW
  • 10.2 FIRST GENERATION CAR-T CELLS
  • 10.3 SECOND GENERATION CAR-T CELLS
  • 10.4 THIRD GENERATION CAR-T CELLS
  • 10.5 FOURTH GENERATION CAR-T CELLS

11 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS

  • 11.1 OVERVIEW
  • 11.2 ANTIGENS ON HEMATOLOGIC MALIGNANCIES
    • 11.2.1 CLUSTER OF DIFFERENTIATION-19 (CD-19)
    • 11.2.2 CLUSTER OF DIFFERENTIATION-30 (CD-30)
    • 11.2.3 CLUSTER OF DIFFERENTIATION-22 (CD-22)
    • 11.2.4 CLUSTER OF DIFFERENTIATION-20 (CD-20)
    • 11.2.5 CLUSTER OF DIFFERENTIATION-33 (CD-33)
  • 11.3 ANTIGENS ON SOLID TUMORS
    • 11.3.1 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER-2)
    • 11.3.2 EPIDERMAL GROWTH FACTOR RECEPTORS VARIANT III (EGFRV-III)
    • 11.3.3 MESOTHELIN (MSLN)
    • 11.3.4 PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
    • 11.3.5 INTERLEUKIN-13RA2 (IL13RA2)
    • 11.3.6 DISIALOGANGLIOSIDE 2 (GD2)
    • 11.3.7 GLYPICAN-3 (GPC3)
    • 11.3.8 OTHERS
  • 11.4 OTHERS

12 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND

  • 12.1 OVERVIEW
  • 12.2 YESCARTA
  • 12.3 KYMRIAH
  • 12.4 TECARTUS
  • 12.5 OTHERS

13 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION

  • 13.1 OVERVIEW
  • 13.2 FOLLICULAR LYMPHOMA
  • 13.3 DIFFUSE LARGE B-CELL LYMPHOMA
  • 13.4 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)
  • 13.5 MANTLE CELL LYMPHOMA
  • 13.6 MULTIPLE MYELOMA
  • 13.7 HEMATOLOGIC MALIGNANCIES
    • 13.7.1 LEUKEMIA
    • 13.7.2 LYMPHOMA
    • 13.7.3 MYELOMA
    • 13.7.4 OTHERS
  • 13.8 LUNG CANCER
  • 13.9 CHRONIC LYMPHOCYTIC LEUKEMIA
  • 13.10 GASTRIC CANCER
  • 13.11 PANCREATIC CANCER
  • 13.12 BREAST CANCER
  • 13.13 OTHERS

14 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 SPECIALTY CLINICS
  • 14.4 OTHERS

15 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 OTHERS

16 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET BY GEOGRAPHY

  • 16.1 OVERVIEW
  • 16.2 NORTH AMERICA
    • 16.2.1 U.S
    • 16.2.2 CANADA
    • 16.2.3 MEXICO
  • 16.3 EUROPE
    • 16.3.1 GERMANY
    • 16.3.2 U.K
    • 16.3.3 FRANCE
    • 16.3.4 ITALY
    • 16.3.5 SPAIN
    • 16.3.6 NETHERLANDS
    • 16.3.7 RUSSIA
    • 16.3.8 SWITZERLAND
    • 16.3.9 BELGIUM
    • 16.3.10 TURKEY
    • 16.3.11 AUSTRIA
    • 16.3.12 NORWAY
    • 16.3.13 HUNGARY
    • 16.3.14 LITHUANIA
    • 16.3.15 IRELAND
    • 16.3.16 POLAND
    • 16.3.17 REST OF EUROPE
  • 16.4 ASIA-PACIFIC
    • 16.4.1 JAPAN
    • 16.4.2 AUSTRALIA
    • 16.4.3 SINGAPORE
    • 16.4.4 CHINA
    • 16.4.5 SOUTH KOREA
    • 16.4.6 INDIA
    • 16.4.7 MALAYSIA
    • 16.4.8 THAILAND
    • 16.4.9 INDONESIA
    • 16.4.10 PHILIPPINES
    • 16.4.11 VIETNAM
    • 16.4.12 REST OF ASIA-PACIFIC
  • 16.5 SOUTH AMERICA
    • 16.5.1 BRAZIL
    • 16.5.2 ARGENTINA
    • 16.5.3 PERU
    • 16.5.4 REST OF SOUTH AMEERICA
  • 16.6 MIDDLE EAST AND AFRICA
    • 16.6.1 SAUDI ARABIA
    • 16.6.2 UAE
    • 16.6.3 SOUTH AFRICA
    • 16.6.4 ISRAEL
    • 16.6.5 KUWAIT
    • 16.6.6 EGYPT
    • 16.6.7 REST OF MIDDLE EAST AND AFRICA

17 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 SWOT ANALYSIS

19 COMPANY PROFILE

  • 19.1 KITE PHARMA (A SUBSIDIARY OF GILEAD SCIENCES, INC.)
    • 19.1.1 COMPANY SNAPSHOT
    • 19.1.2 REVENUE ANALYSIS
    • 19.1.3 COMPANY SHARE ANALYSIS
    • 19.1.4 PRODUCT PORTFOLIO
    • 19.1.5 RECENT DEVELOPMENTS
  • 19.2 NOVARTIS AG
    • 19.2.1 COMPANY SNAPSHOT
    • 19.2.2 REVENUE ANALYSIS
    • 19.2.3 COMPANY SHARE ANALYSIS
    • 19.2.4 PRODUCT PORTFOLIO
    • 19.2.5 RECENT DEVELOPMENTS
  • 19.3 ABBVIE INC.
    • 19.3.1 COMPANY SNAPSHOT
    • 19.3.2 REVENUE ANALYSIS
    • 19.3.3 PRODUCT PORTFOLIO
    • 19.3.4 RECENT DEVELOPMENTS
  • 19.4 ADAPTIMMUNE THERAPEUTICS PLC
    • 19.4.1 COMPANY SNAPSHOT
    • 19.4.2 REVENUE ANALYSIS
    • 19.4.3 PRODUCT PORTFOLIO
    • 19.4.4 RECENT DEVELOPMENTS
  • 19.5 AMGEN INC.
    • 19.5.1 COMPANY SNAPSHOT
    • 19.5.2 REVENUE ANALYSIS
    • 19.5.3 PIPELINE PRODUCT PORTFOLIO
    • 19.5.4 RECENT DEVELOPMENTS
  • 19.6 ATARA BIOTHERAPEUTICS, INC.
    • 19.6.1 COMPANY SNAPSHOT
    • 19.6.2 PIPELINE PRODUCT PORTFOLIO
    • 19.6.3 RECENT DEVELOPMENTS
  • 19.7 AURORA BIOPHARMA
    • 19.7.1 COMPANY SNAPSHOT
    • 19.7.2 PIPELINE PRODUCT PORTFOLIO
    • 19.7.3 RECENT DEVELOPMENTS
  • 19.8 AUTOLUS
    • 19.8.1 COMPANY SNAPSHOT
    • 19.8.2 PRODUCT PORTFOLIO
    • 19.8.3 RECENT DEVELOPMENTS
  • 19.9 BELLICUM PHAMACEUTICALS, INC.
    • 19.9.1 COMPANY SNAPSHOT
    • 19.9.2 REVENUE ANALYSIS
    • 19.9.3 PRODUCT PORTFOLIO
    • 19.9.4 RECENT DEVELOPMENTS
  • 19.10 BIOATLA INC.
    • 19.10.1 COMPANY SNAPSHOT
    • 19.10.2 PRODUCT PORTFOLIO
    • 19.10.3 RECENT DEVELOPMENTS
  • 19.11 BLUEBIRD BIO, INC.
    • 19.11.1 COMPANY SNAPSHOT
    • 19.11.2 REVENUE ANALYSIS
    • 19.11.3 PRODUCT PORTFOLIO
    • 19.11.4 RECENT DEVELOPMENTS
  • 19.12 BRISTOL-MYERS SQUIBB COMPANY
    • 19.12.1 COMPANY SNAPSHOT
    • 19.12.2 REVENUE ANALYSIS
    • 19.12.3 PRODUCT PORTFOLIO
    • 19.12.4 RECENT DEVELOPMENTS
  • 19.13 CARINA BIOTECH
    • 19.13.1 COMPANY SNAPSHOT
    • 19.13.2 PRODUCT PORTFOLIO
    • 19.13.3 RECENT DEVELOPMENTS
  • 19.14 CARTHERICS PTY LTD
    • 19.14.1 COMPANY SNAPSHOT
    • 19.14.2 PRODUCT PORTFOLIO
    • 19.14.3 RECENT DEVELOPMENTS
  • 19.15 CARTESIAN THERAPEUTICS, INC.
    • 19.15.1 COMPANY SNAPSHOT
    • 19.15.2 PIPELINE PRODUCT PORTFOLIO
    • 19.15.3 RECENT DEVELOPMENTS
  • 19.16 CELLECTIS SA
    • 19.16.1 COMPANY SNAPSHOT
    • 19.16.2 REVENUE ANALYSIS
    • 19.16.3 PRODUCT PORTFOLIO
    • 19.16.4 RECENT DEVELOPMENTS
  • 19.17 CELYAD ONCOLOGY SA
    • 19.17.1 COMPANY SNAPSHOT
    • 19.17.2 PIPELINE PRODUCT PORTFOLIO
    • 19.17.3 RECENT DEVELOPMENTS
  • 19.18 JOHNSON & JOHNSON SERVICES, INC.
    • 19.18.1 COMPANY SNAPSHOT
    • 19.18.2 REVENUE ANALYSIS
    • 19.18.3 PRODUCT PORTFOLIO
    • 19.18.4 RECENT DEVELOPMENTS
  • 19.19 SORRENTO THERAPEUTICS, INC.
    • 19.19.1 COMPANY SNAPSHOT
    • 19.19.2 PIPELINE PRODUCT PORTFOLIO
    • 19.19.3 RECENT DEVELOPMENTS
  • 19.20 TC BIOPHARM LIMITED
    • 19.20.1 COMPANY SNAPSHOT
    • 19.20.2 PIPELINE PRODUCT PORTFOLIO
    • 19.20.3 RECENT DEVELOPMENTS
  • 19.21 TESSA THERAPEUTICS LTD.
    • 19.21.1 COMPANY SNAPSHOT
    • 19.21.2 PIPELINE PRODUCT PORTFOLIO
    • 19.21.3 RECENT DEVELOPMENTS
  • 19.22 TMUNITY THERAPEUTICS
    • 19.22.1 COMPANY SNAPSHOT
    • 19.22.2 PIPELINE PRODUCT PORTFOLIO
    • 19.22.3 RECENT DEVELOPMENTS
  • 19.23 MUSTANG BIO
    • 19.23.1 COMPANY SNAPSHOT
    • 19.23.2 PIPELINE PRODUCT PORTFOLIO
    • 19.23.3 RECENT DEVELOPMENTS
  • 19.24 XYPHOS (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
    • 19.24.1 COMPANY SNAPSHOT
    • 19.24.2 REVENUE ANALYSIS
    • 19.24.3 PIPELINE PRODUCT PORTFOLIO
    • 19.24.4 RECENT DEVELOPMENTS
  • 19.25 ZIOPHARM ONCOLOGY, INC.
    • 19.25.1 COMPANY SNAPSHOT
    • 19.25.2 PRODUCT PORTFOLIO
    • 19.25.3 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS
  • TABLE 2 BELOW PROVIDED ARE THE ALTERNATIVE CHEMOTHERAPIES OF CAR-T CELL THERAPY:
  • TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)
  • TABLE 4 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET, BY MOLECULE, 2019-2028 (USD MILLION)
  • TABLE 5 GLOBAL AUTOLOGOUS CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 6 GLOBAL ALLOGENEIC CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 7 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET, BY STRUCTURE, 2019-2028 (USD MILLION)
  • CELYAD IS ENGAGED IN THE MANUFACTURING OF CYAD-211, A FIRST GENERATION CAR-T CELL THERAPY EXPRESSING BCMA TARGETING CHIMERIC ANTIGEN RECEPTOR WHICH INTERFERES WITH THE EXPRESSION OF THE CD3Z OF T CELL RECEPTOR COMPLEX.
  • TABLE 8 GLOBAL FIRST GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 9 GLOBAL SECOND GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 10 GLOBAL THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 11 GLOBAL THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 12 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 13 GLOBAL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 14 GLOBAL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON HEMATOLOGIC MALIGNANCIES, 2019-2028 (USD MILLION)
  • TABLE 15 GLOBAL ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
  • TABLE 16 GLOBAL ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON SOLID TUMORS, 2019-2028 (USD MILLION)
  • TABLE 17 GLOBAL OTHERS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
  • TABLE 18 GLOBAL YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 19 GLOBAL YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 20 GLOBAL KYMRIAH IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 21 GLOBAL TECARTUS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 22 GLOBAL OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 23 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
  • TABLE 24 GLOBAL FOLLICULAR LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
  • TABLE 25 GLOBAL DIFFUSE LARGE B-CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 26 GLOBAL ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 27 GLOBAL MANTLE CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 28 GLOBAL MULTIPLE MYELOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 29 GLOBAL HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 30 GLOBAL HEMATOLOGIC MALIGNANCIES ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 31 GLOBAL LUNG CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 32 GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 33 GLOBAL GASTRIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 34 GLOBAL PANCREATIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 35 GLOBAL BREAST CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 36 GLOBAL OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 37 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 38 GLOBAL HOSPITALS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
  • TABLE 39 GLOBAL SPECIALTY CLINICS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 40 GLOBAL OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 41 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 42 GLOBAL HOSPITAL PHARMACY IN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2028 (USD MILLION)
  • TABLE 43 GLOBAL OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 44 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET, BY REGION , 2021-2028 (USD MILLION)
  • TABLE 45 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 46 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 47 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 48 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 49 NORTH AMERICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 50 NORTH AMERICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 51 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 52 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 53 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 54 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 55 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 56 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 57 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 58 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 59 U.S ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 60 U.S ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 61 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 62 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 63 U.S HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 64 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 65 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 66 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 67 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 68 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 69 CANADA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 70 CANADA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 71 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 72 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 73 CANADA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 74 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 75 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 76 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 77 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 78 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 79 MEXICO ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 80 MEXICO ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 81 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 82 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 83 MEXICO HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 84 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 85 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 86 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 87 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 88 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 89 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 90 EUROPE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 91 EUROPE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 92 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 93 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 94 EUROPE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 95 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 96 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 97 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 98 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 99 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 100 GERMANY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 101 GERMANY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 102 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 103 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 104 GERMANY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 105 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 106 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 107 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 108 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 109 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 110 U.K ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 111 U.K ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 112 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 113 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 114 U.K HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 115 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 116 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 117 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 118 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 119 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 120 FRANCE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 121 FRANCE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 122 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 123 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 124 FRANCE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 125 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 126 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 127 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 128 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 129 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 130 ITALY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 131 ITALY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 132 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 133 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 134 ITALY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 135 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 136 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 137 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 138 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 139 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 140 SPAIN ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 141 SPAIN ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 142 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 143 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 144 SPAIN HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 145 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 146 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 147 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 148 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 149 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 150 NETHERLANDS ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 151 NETHERLANDS ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 152 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 153 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 154 NETHERLANDS HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 155 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 156 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 157 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 158 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 159 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 160 RUSSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 161 RUSSIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 162 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 163 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 164 RUSSIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 165 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 166 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 167 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 168 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 169 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 170 SWITZERLAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 171 SWITZERLAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 172 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 173 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 174 SWITZERLAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 175 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 176 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 177 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 178 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 179 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 180 BELGIUM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 181 BELGIUM ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 182 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 183 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 184 BELGIUM HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 185 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 186 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 187 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 188 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 189 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 190 TURKEY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 191 TURKEY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 192 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 193 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 194 TURKEY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 195 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 196 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 197 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 198 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 199 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 200 AUSTRIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 201 AUSTRIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 202 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 203 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 204 AUSTRIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 205 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 206 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 207 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 208 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 209 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 210 NORWAY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 211 NORWAY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 212 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 213 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 214 NORWAY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 215 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 216 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 217 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 218 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 219 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 220 HUNGARY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 221 HUNGARY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 222 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 223 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 224 HUNGARY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 225 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 226 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 227 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 228 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 229 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 230 LITHUANIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 231 LITHUANIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 232 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 233 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 234 LITHUANIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 235 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 236 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 237 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 238 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 239 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 240 IRELAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 241 IRELAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 242 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 243 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 244 IRELAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 245 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 246 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 247 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 248 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 249 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 250 POLAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 251 POLAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 252 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 253 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 254 POLAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 255 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 256 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 257 REST OF EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 258 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 259 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 260 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 261 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 262 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 263 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 264 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 265 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 266 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 267 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 268 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 269 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 270 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 271 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 272 JAPAN ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 273 JAPAN ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 274 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 275 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 276 JAPAN HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 277 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 278 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 279 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 280 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 281 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 282 AUSTRALIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 283 AUSTRALIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 284 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 285 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 286 AUSTRALIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 287 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 288 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 289 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 290 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 291 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 292 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 293 SINGAPORE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 294 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 295 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 296 SINGAPORE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 297 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 298 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 299 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 300 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 301 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 302 CHINA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 303 CHINA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 304 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 305 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 306 CHINA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 307 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 308 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 309 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 310 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 311 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 312 SOUTH KOREA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 313 SOUTH KOREA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 314 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 315 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 316 SOUTH KOREA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 317 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 318 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 319 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 320 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 321 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 322 INDIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 323 INDIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 324 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 325 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 326 INDIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 327 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 328 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 329 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 330 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 331 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 332 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 333 MALAYSIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 334 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 335 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 336 MALAYSIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 337 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 338 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 339 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 340 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 341 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 342 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 343 THAILAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 344 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 345 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 346 THAILAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 347 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 348 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 349 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 350 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 351 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 352 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 353 INDONESIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 354 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 355 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 356 INDONESIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 357 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 358 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 359 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 360 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 361 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 362 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 363 PHILIPPINES ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 364 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 365 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 366 PHILIPPINES HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 367 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 368 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 369 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 370 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 371 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 372 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 373 VIETNAM ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 374 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 375 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 376 VIETNAM HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 377 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 378 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 379 REST OF ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 380 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 381 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 382 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 383 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 384 SOUTH AMERICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 385 SOUTH AMERICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 386 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 387 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 388 SOUTH AMERICA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 389 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 390 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 391 BRAZIL CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 392 BRAZIL CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 393 BRAZIL CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 394 BRAZIL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 395 BRAZIL ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 396 BRAZIL CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 397 BRAZIL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 398 BRAZIL HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 399 BRAZIL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 400 BRAZIL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 401 ARGENTINA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 402 ARGENTINA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 403 ARGENTINA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 404 ARGENTINA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 405 ARGENTINA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 406 ARGENTINA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 407 ARGENTINA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 408 ARGENTINA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 409 ARGENTINA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 410 ARGENTINA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 411 PERU CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 412 PERU CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 413 PERU CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 414 PERU ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 415 PERU ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 416 PERU CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 417 PERU CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 418 PERU HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 419 PERU CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 420 PERU CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 421 REST OF SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 422 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 423 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 424 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 425 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 426 MIDDLE EAST AND AFRICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 427 MIDDLE EAST AND AFRICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 428 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 429 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 430 MIDDLE EAST AND AFRICA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 431 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 432 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 433 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 434 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 435 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 436 SAUDI ARABIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 437 SAUDI ARABIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 438 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 439 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 440 SAUDI ARABIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 441 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 442 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 443 UAE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 444 UAE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 445 UAE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 446 UAE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 447 UAE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 448 UAE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 449 UAE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 450 UAE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 451 UAE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 452 UAE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 453 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 454 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 455 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 456 SOUTH AFRICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 457 SOUTH AFRICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 458 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 459 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 460 SOUTH AFRICA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 461 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 462 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 463 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 464 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 465 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 466 ISRAEL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 467 ISRAEL ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 468 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 469 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 470 ISRAEL HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 471 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 472 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 473 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 474 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 475 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 476 KUWAIT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 477 KUWAIT ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 478 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 479 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 480 KUWAIT HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 481 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 482 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 483 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
  • TABLE 484 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
  • TABLE 485 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 486 EGYPT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 487 EGYPT ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
  • TABLE 488 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
  • TABLE 489 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 490 EGYPT HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
  • TABLE 491 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 492 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 493 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION 45
  • FIGURE 2 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION 48
  • FIGURE 3 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS 49
  • FIGURE 4 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 50
  • FIGURE 5 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 50
  • FIGURE 6 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING 51
  • FIGURE 7 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 53
  • FIGURE 8 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID 54
  • FIGURE 9 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS 56
  • FIGURE 10 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: MARKET PRODUCT COVERAGE GRID 57
  • FIGURE 11 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION 62
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL CAR-T CELL THERAPY TREATMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028 63
  • FIGURE 13 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE GLOBAL CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 64
  • FIGURE 14 AUTOLOGUS CAR-T CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CAR-T CELL THERAPY TREATMENT MARKET IN 2021 & 2028 64
  • FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE CAR-T CELL THERAPY TREATMENT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 65
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CAR-T CELL THERAPY TREATMENT MARKET 71
  • FIGURE 17 NEW CANCER CASES WORLDWIDE, (2018) 73
  • FIGURE 18 GLOBAL CANCER INCIDENCE (2018) 74
  • FIGURE 19 CANCER DEATH BY TYPE (IN MILLION), WORLD, 2017 75
  • FIGURE 20 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2021 90
  • FIGURE 21 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2019-2028 (USD MILLION) 91
  • FIGURE 22 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2021-2028) 91
  • FIGURE 23 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE 92
  • FIGURE 24 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2021 96
  • FIGURE 25 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2019-2028 (USD MILLION) 97
  • FIGURE 26 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2021-2028) 97
  • FIGURE 27 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE 98
  • FIGURE 28 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2021 104
  • FIGURE 29 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2019-2028 (USD MILLION) 105
  • FIGURE 30 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, CAGR (2021-2028) 105
  • FIGURE 31 GLOBAL CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, LIFELINE CURVE 106
  • FIGURE 32 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020 113
  • FIGURE 33 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020-2028 (USD MILLION) 114
  • FIGURE 34 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2020-2028) 114
  • FIGURE 35 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE 115
  • FIGURE 36 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020 121
  • FIGURE 37 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020-2028 (USD MILLION) 122
  • FIGURE 38 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, CAGR (2020-2028) 122
  • FIGURE 39 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE 123
  • FIGURE 40 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020 136
  • FIGURE 41 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION) 137
  • FIGURE 42 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, CAGR (2020-2028) 137
  • FIGURE 43 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, LIFELINE CURVE 138
  • FIGURE 44 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020 142
  • FIGURE 45 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION) 143
  • FIGURE 46 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028) 143
  • FIGURE 47 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 144
  • FIGURE 48 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020) 148
  • FIGURE 49 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020) 150
  • FIGURE 50 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028) 150
  • FIGURE 51 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028) 151
  • FIGURE 52 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028) 151
  • FIGURE 53 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020) 153
  • FIGURE 54 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020) 155
  • FIGURE 55 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028) 155
  • FIGURE 56 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028) 156
  • FIGURE 57 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028) 156
  • FIGURE 58 EUROPE CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020) 173
  • FIGURE 59 EUROPE CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020) 175
  • FIGURE 60 EUROPE CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028) 175
  • FIGURE 61 EUROPE CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028) 176
  • FIGURE 62 EUROPE CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028) 176
  • FIGURE 63 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020) 247
  • FIGURE 64 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020) 249
  • FIGURE 65 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028) 249
  • FIGURE 66 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028) 250
  • FIGURE 67 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028) 250
  • FIGURE 68 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020) 301
  • FIGURE 69 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020) 303
  • FIGURE 70 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028) 303
  • FIGURE 71 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028) 304
  • FIGURE 72 SOUTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028) 304
  • FIGURE 73 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020) 322
  • FIGURE 74 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020) 324
  • FIGURE 75 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028) 324
  • FIGURE 76 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028) 325
  • FIGURE 77 MIDDLE EAST AND AFRICA CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028) 325
  • FIGURE 78 GLOBAL CAR-T CELL THERAPY TREATMENT MARKET: COMPANY SHARE 2020 (%) 355
  • FIGURE 79 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY SHARE 2020 (%) 356
  • FIGURE 80 EUROPE CAR-T CELL THERAPY TREATMENT MARKET: COMPANY SHARE 2020 (%) 357
  • FIGURE 81 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: COMPANY SHARE 2020 (%) 358